Evolus (NASDAQ:EOLS) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Evolus (NASDAQ:EOLS - Free Report) in a research note published on Thursday morning,Benzinga reports. They currently have a $22.00 target price on the stock.

EOLS has been the topic of a number of other research reports. BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock. Barclays raised their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus has a consensus rating of "Buy" and an average target price of $23.75.

Evolus Price Performance

Shares of NASDAQ EOLS traded down $0.29 during midday trading on Thursday, reaching $9.80. The company's stock had a trading volume of 1,361,358 shares, compared to its average volume of 672,080. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market cap of $631.82 million, a P/E ratio of -10.77 and a beta of 1.11. The business's 50 day moving average price is $11.66 and its two-hundred day moving average price is $12.54. Evolus has a fifty-two week low of $8.67 and a fifty-two week high of $17.82.

Insider Buying and Selling at Evolus

In other news, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the transaction, the insider now owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the transaction, the insider now owns 508,619 shares in the company, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,575 shares of company stock worth $794,369. 5.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Evolus

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Evolus by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company's stock valued at $347,000 after purchasing an additional 1,094 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after buying an additional 1,291 shares during the last quarter. Rhumbline Advisers lifted its holdings in Evolus by 2.2% in the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock valued at $885,000 after buying an additional 1,762 shares during the period. Tradition Wealth Management LLC lifted its holdings in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock valued at $144,000 after buying an additional 2,000 shares during the period. Finally, MetLife Investment Management LLC boosted its position in Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock valued at $378,000 after acquiring an additional 2,044 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.